A Randomized Clinical Trial of Human Papillomavirus Test-and-Treat as Compared to Cytology-Based Screening for Prevention of Cervical Cancer Among Women With Human Immunodeficiency Virus: AIDS Clinical Trials Group Protocol A5282

Timothy Wilkin & Cynthia Firnhaber et al.

Abstract

Background

Cytology-based cervical cancer screening followed by confirmation and treatment of biopsy-proven high-grade squamous intraepithelial lesions (bHSIL) is difficult to implement in resource-constrained settings. We hypothesized that high-risk human papillomavirus (hrHPV) testing followed by immediate cryotherapy of women with hrHPV (HPV screen-and-treat) may improve outcomes.

Methods

Randomized, open-label, phase 2, multinational clinical trial enrolling women with human immunodeficiency virus (HIV) age 18 or older with cervical hrHPV and having no cervical lesions or lesions appropriate for cryotherapy. Women were randomized to immediate cryotherapy (Arm A) or cytology-based screening (Arm B). For Arm A, cervical biopsies were obtained followed by cervical cryotherapy, and in Arm B, women with abnormal cytology underwent colposcopy followed by loop electroexcision procedure (LEEP) if bHSIL was detected. Women were followed through 30 months. The primary outcome was time to bHSIL detected from Month 6 through study completion.

Results

In total, 288 women (145 in Arm A, 143 in Arm B) were randomized: median age 35 years, 84% on antiretroviral therapy, median CD4 501 cells/mm3. In Arm A, 39 (27%) of women had bHSIL at entry, and in Arm B, 88 (62%) had abnormal cytology, 22 (15%) were diagnosed with bHSIL, 12 (8%) underwent LEEP. In follow-up, 30 (21%) and 31 (22%) developed bHSIL; time to bHSIL was similar between arms (P=.94). The prevalence of hrHPV at Month 6 was similar between arms (61% and 70%, P=.13).

Conclusions

HPV test-and-treat was not associated with improved bHSIL outcomes as compared to cytology-based screening. More effective treatment options are required to improve outcomes from screen-and-treat programs.

Clinical Trials Registration

NCT01315363.

Authors
Timothy Wilkin, Huichao Chen, Vikrant Sahasrabuddhe, Roy Matining, Rosie Mngqibisa, Lameck Chinula, Yamikani Mbilizi, Tsitsi Magure, Ayotunde E Omoz-Oarhe, Mohammed Rassool, Cynthia Riviere, Rhamesh Bhosale, Sheela Godbole, Reena Naranjo, Robert Coombs, Pamela Michelow, Catherine Godfrey, Cynthia Firnhaber
Funding
University of North Carolina Global HIV Prevention and Treatment Clinical Trials UnitBotswana-Harvard T.H. Chan School of Public Health AIDS Initiative Partnership CTUUCSD Collaborative Clinical Trials UnitStatistical and Data Management Center (SDMC), Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)The Johns Hopkins University-Blantyre Clinical Trials UnitAIDS Clinical Trials Group NetworkPHRU-Setshaba Clinical Trials UnitWits HIV Research Group CLINICAL TRIAL UNIT (CTU) reapplicationLeadership and Operations Center (LOC), AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases FundingPresidential Emergency Plan For AIDS Relief Grant AI069417Presidential Emergency Plan For AIDS Relief Grant AI069421Presidential Emergency Plan For AIDS Relief Grant AI069423Presidential Emergency Plan For AIDS Relief Grant AI069432Presidential Emergency Plan For AIDS Relief Grant AI069438Presidential Emergency Plan For AIDS Relief Grant AI069453Presidential Emergency Plan For AIDS Relief Grant AI069456Presidential Emergency Plan For AIDS Relief Grant AI069463Presidential Emergency Plan For AIDS Relief Grant AI069465Presidential Emergency Plan For AIDS Relief Grant AI069471Presidential Emergency Plan For AIDS Relief Grant AI069497Presidential Emergency Plan For AIDS Relief Grant AI069518Presidential Emergency Plan For AIDS Relief Grant AI069521

NIAID NIH HHS

UM1 AI069423

NIAID NIH HHS

UM1 AI069456

NIAID NIH HHS

UM1 AI069432

NIAID NIH HHS

UM1 AI068634

NIAID NIH HHS

UM1 AI069518

NIAID NIH HHS

U01 AI068636

NIAID NIH HHS

UM1 AI069453

NIAID NIH HHS

UM1 AI069463

NIAID NIH HHS

UM1 AI068636